Swiss digital therapy specialist Oviva has raised $21 million in second-round financing to help expand the use of smartphone-based tools designed to help people with diabetes manage their c
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh